{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "17197433", "DateCompleted": {"Year": "2007", "Month": "05", "Day": "23"}, "DateRevised": {"Year": "2024", "Month": "03", "Day": "17"}, "Article": {"ArticleDate": [{"Year": "2006", "Month": "12", "Day": "29"}], "Language": ["eng"], "ELocationID": [], "Journal": {"ISSN": "0006-4971", "JournalIssue": {"Volume": "109", "Issue": "8", "PubDate": {"Year": "2007", "Month": "Apr", "Day": "15"}}, "Title": "Blood", "ISOAbbreviation": "Blood"}, "ArticleTitle": "Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo.", "Pagination": {"StartPage": "3441", "EndPage": "3450", "MedlinePgn": "3441-50"}, "Abstract": {"AbstractText": ["Studies have documented the potential antitumor activities of oridonin, a compound extracted from medicinal herbs. However, whether oridonin can be used in the selected setting of hematology/oncology remains obscure. Here, we reported that oridonin induced apoptosis of t(8;21) acute myeloid leukemic (AML) cells. Intriguingly, the t(8;21) product AML1-ETO (AE) fusion protein, which plays a critical role in leukemogenesis, was degraded with generation of a catabolic fragment, while the expression pattern of AE target genes investigated could be reprogrammed. The ectopic expression of AE enhanced the apoptotic effect of oridonin in U937 cells. Preincubation with caspase inhibitors blocked oridonin-triggered cleavage of AE, while substitution of Ala for Asp at residues 188 in ETO moiety of the fusion abrogated AE degradation. Furthermore, oridonin prolonged lifespan of C57 mice bearing truncated AE-expressing leukemic cells without suppression of bone marrow or reduction of body weight of animals, and exerted synergic effects while combined with cytosine arabinoside. Oridonin also inhibited tumor growth in nude mice inoculated with t(8;21)-harboring Kasumi-1 cells. These results suggest that oridonin may be a potential antileukemia agent that targets AE oncoprotein at residue D188 with low adverse effect, and may be helpful for the treatment of patients with t(8;21) AML."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Road II, Shanghai 200025, China. zhou_guangbiao@gibh.org"}], "Identifier": [], "LastName": "Zhou", "ForeName": "Guang-Biao", "Initials": "GB"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Kang", "ForeName": "Hui", "Initials": "H"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Wang", "ForeName": "Lan", "Initials": "L"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Gao", "ForeName": "Li", "Initials": "L"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Liu", "ForeName": "Ping", "Initials": "P"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Xie", "ForeName": "Jun", "Initials": "J"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Zhang", "ForeName": "Feng-Xiang", "Initials": "FX"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Weng", "ForeName": "Xiang-Qin", "Initials": "XQ"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Shen", "ForeName": "Zhi-Xiang", "Initials": "ZX"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Chen", "ForeName": "Jue", "Initials": "J"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Gu", "ForeName": "Long-Jun", "Initials": "LJ"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Yan", "ForeName": "Ming", "Initials": "M"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Zhang", "ForeName": "Dong-Er", "Initials": "DE"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Chen", "ForeName": "Sai-Juan", "Initials": "SJ"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Wang", "ForeName": "Zhen-Yi", "Initials": "ZY"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Chen", "ForeName": "Zhu", "Initials": "Z"}], "GrantList": [{"GrantID": "R01 CA096735", "Acronym": "CA", "Agency": "NCI NIH HHS", "Country": "United States"}, {"GrantID": "CA 96735", "Acronym": "CA", "Agency": "NCI NIH HHS", "Country": "United States"}], "PublicationTypeList": ["Journal Article", "Research Support, N.I.H., Extramural", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Blood", "NlmUniqueID": "7603509", "ISSNLinking": "0006-4971"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "AML1-ETO fusion protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Core Binding Factor Alpha 2 Subunit"}, {"RegistryNumber": "0", "NameOfSubstance": "Diterpenes"}, {"RegistryNumber": "0", "NameOfSubstance": "Diterpenes, Kaurane"}, {"RegistryNumber": "0", "NameOfSubstance": "Oncogene Proteins, Fusion"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}, {"RegistryNumber": "0", "NameOfSubstance": "RUNX1 Translocation Partner 1 Protein"}, {"RegistryNumber": "04079A1RDZ", "NameOfSubstance": "Cytarabine"}, {"RegistryNumber": "0APJ98UCLQ", "NameOfSubstance": "oridonin"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": ["genetics"], "DescriptorName": "Chromosomes, Human, Pair 21"}, {"QualifierName": ["genetics"], "DescriptorName": "Chromosomes, Human, Pair 8"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "Core Binding Factor Alpha 2 Subunit"}, {"QualifierName": ["agonists", "pharmacology"], "DescriptorName": "Cytarabine"}, {"QualifierName": ["agonists", "chemistry", "pharmacology"], "DescriptorName": "Diterpenes"}, {"QualifierName": ["agonists", "chemistry", "pharmacology"], "DescriptorName": "Diterpenes, Kaurane"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": [], "DescriptorName": "Drug Synergism"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy", "metabolism", "pathology"], "DescriptorName": "Leukemia, Myeloid, Acute"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Mice, Nude"}, {"QualifierName": ["drug therapy", "metabolism", "pathology"], "DescriptorName": "Neoplasms, Experimental"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "Oncogene Proteins, Fusion"}, {"QualifierName": ["agonists", "chemistry", "pharmacology"], "DescriptorName": "Plant Extracts"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "RUNX1 Translocation Partner 1 Protein"}, {"QualifierName": [], "DescriptorName": "Translocation, Genetic"}, {"QualifierName": [], "DescriptorName": "U937 Cells"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Henan Robdosia Coop Group. Efficacy of Rabdosia rubescens in treating 101 patients with esophageal or gastric cardiac carcinoma. J Henan Med Coll. 1980;5:31\u201337."}, {"Citation": "Tang W, Eisenbrand G. Berlin, Germany: Springer-Verlag; 1992. Chinese Drugs of Plant Origin:Chemistry, Pharmacology and Use in Traditional and Modern Medicine."}, {"Citation": "Wang R, Fan K, Fan Q, et al. Clinical observation of 437 cases with esophageal cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1989;9:740\u2013741."}, {"Citation": "Wang R, Wang L. Efficacy of Rabdosia rubescens in treating 95 cases with esophageal and gastric cardiac cancer. Cancer Res Prev Treatment. 1994;11:86\u201387."}, {"Citation": "Wang R, Gao B, Xiong M, et al. Studies on synergistic effect of Rabdosia Rubescens and chemotherapy on esophageal cancer. Chin J Oncol. 1986;8:297\u2013298.", "ArticleIdList": ["2428570"]}, {"Citation": "Fujita T, Takeda Y, Sun HD, et al. Cytotoxic and antitumor activities of Rabdosia diterpenoids. Planta Med. 1988;54:414\u2013417.", "ArticleIdList": ["3200934"]}, {"Citation": "Fujita E, Fujita T, Katayama H, Shibuya M. Terpenoids, part XV: structure and absolute configuration of oridonin isolated from Isodon japonicus trichocarpus. J Chem Soc (C) 1970;21:1674\u20131681."}, {"Citation": "Henan Medical Institute; Henan Medical College; Yunnan Institute of Botany. Oridonin: a new antitumor subject. Chin Sci Bull. 1978;23:53\u201356."}, {"Citation": "Li XT, Lin C, Li PY, Zhang TM. Comparative study on the sensitivities of seven human cancer cell lines to rubescensine A. Acta Pharmaceutica Sinica. 1985;20:243\u2013246.", "ArticleIdList": ["4072693"]}, {"Citation": "Zhang CL, Wu LJ, Zuo HJ, et al. Cytochrome c release from oridonin-treated apoptotic A375-S2 cells is dependent on p53 and extracellular signal-regulated kinase activation. J Pharmacol Sci. 2004;96:155\u2013163.", "ArticleIdList": ["15492467"]}, {"Citation": "Ikezoe T, Chen SS, Tong XJ, et al. Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol. 2003;23:1187\u20131193.", "ArticleIdList": ["12964003"]}, {"Citation": "Chen S, Gao J, Halicka HD, et al. The cytostatic and cytotoxic effects of oridonin (Rubescenin), a diterpenoid from Rabdosia rubescens, on tumor cells of different lineage. Int J Oncol. 2005;26:579\u2013588.", "ArticleIdList": ["15703811"]}, {"Citation": "Fuji K, Node M, Sai M, Terpenoids L, III, et al. Antitumor activity of trichorabdals and related compounds. Chem Pharm Bull (Tokyo) 1989;37:1472\u20131476.", "ArticleIdList": ["2776235"]}, {"Citation": "Fujita E, Nagao Y, Node M, et al. Antitumor activity of the Isodon diterpenoids: structural requirements for the activity. Experientia. 1976;32:203\u2013206.", "ArticleIdList": ["1269612"]}, {"Citation": "Liu JJ, Huang RW, Lin DJ, et al. Anti-proliferative effects of oridonin on SPC-A-1 cells and its mechanism of action. J Int Med Res. 2004;32:617\u2013625.", "ArticleIdList": ["15587755"]}, {"Citation": "Zhang CL, Wu LJ, Tashiro S, Onodera S, Ikejima T. Oridonin induces apoptosis of HeLa cells via altering expression of Bcl-2/Bax and activating caspase-3/ICAD pathway. Acta Pharmacol Sin. 2004;25:691\u2013698.", "ArticleIdList": ["15132839"]}, {"Citation": "Leung CH, Grill SP, Lam W, et al. Novel mechanism of inhibition of nuclear factor-{kappa}B DNA-binding activity by diterpenoids isolated from isodon rubescens. Mol Pharmacol. 2005;68:286\u2013297.", "ArticleIdList": ["15872117"]}, {"Citation": "Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet. 2002;3:179\u2013198.", "ArticleIdList": ["12194988"]}, {"Citation": "Peggs K, Mackinnon S. Imatinib mesylate: the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med. 2003;348:1048\u20131050.", "ArticleIdList": ["12637616"]}, {"Citation": "Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567\u2013572.", "ArticleIdList": ["28034863"]}, {"Citation": "Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996;88:1052\u20131061.", "ArticleIdList": ["8704214"]}, {"Citation": "Licht JD. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene. 2001;20:5660\u20135679.", "ArticleIdList": ["11607817"]}, {"Citation": "Rubnitz JE, Raimondi SC, Halbert AR, et al. Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution's experience. Leukemia. 2002;16:2072\u20132077.", "ArticleIdList": ["12357359"]}, {"Citation": "Amann JM, Nip J, Strom DK, et al. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol. 2001;21:6470\u20136483.", "ArticleIdList": ["PMC99794", "11533236"]}, {"Citation": "Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A. 1998;95:10860\u201310865.", "ArticleIdList": ["PMC27986", "9724795"]}, {"Citation": "Uchida H, Zhang J, Nimer SD. AML1A and AML1B can transactivate the human IL-3 promoter. J Immunol. 1997;158:2251\u20132258.", "ArticleIdList": ["9036972"]}, {"Citation": "Klampfer L, Zhang J, Zelenetz AO, Uchida H, Nimer SD. The AML1/ETO fusion protein activates transcription of BCL-2. Proc Natl Acad Sci U S A. 1996;93:14059\u201314064.", "ArticleIdList": ["PMC19494", "8943060"]}, {"Citation": "Wang YY, Zhou GB, Yin T, et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A. 2005;102:1104\u20131109.", "ArticleIdList": ["PMC545849", "15650049"]}, {"Citation": "Shimizu K, Kitabayashi I, Kamada N, et al. AML1-MTG8 leukemic protein induces the expression of granulocyte colony-stimulating factor (G-CSF) receptor through the up-regulation of CCAAT/enhancer binding protein epsilon. Blood. 2000;96:288\u2013296.", "ArticleIdList": ["10891464"]}, {"Citation": "Frank R, Zhang J, Uchida H, et al. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene. 1995;11:2667\u20132674.", "ArticleIdList": ["8545124"]}, {"Citation": "Peterson LF, Zhang DE. The 8;21 translocation in leukemogenesis. Oncogene. 2004;23:4255\u20134262.", "ArticleIdList": ["15156181"]}, {"Citation": "Higuchi M, O'Brien D, Kumaravelu P, et al. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell. 2002;1:63\u201374.", "ArticleIdList": ["12086889"]}, {"Citation": "Okuda T, Cai Z, Yang S, et al. Expression of a knocked-In AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood. 1998;91:3134\u20133143.", "ArticleIdList": ["9558367"]}, {"Citation": "Yuan Y, Zhou L, Miyamoto T, et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci U S A. 2001;98:10398\u201310403.", "ArticleIdList": ["PMC56972", "11526243"]}, {"Citation": "Fenske TS, Pengue G, Mathews V, et al. Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. Proc Natl Acad Sci U S A. 2004;101:15184\u201315189.", "ArticleIdList": ["PMC524043", "15477599"]}, {"Citation": "de Guzman CG, Warren AJ, Zhang Z, et al. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol. 2002;22:5506\u20135517.", "ArticleIdList": ["PMC133929", "12101243"]}, {"Citation": "Yan M, Burel SA, Peterson LF, et al. From the cover: deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proc Natl Acad Sci U S A. 2004;101:17186\u201317191.", "ArticleIdList": ["PMC535382", "15569932"]}, {"Citation": "Yan M, Kanbe E, Peterson LF, et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med. 2006;12:945\u2013949.", "ArticleIdList": ["16892037"]}, {"Citation": "Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 Trial. Blood. 1998;92:2322\u20132333.", "ArticleIdList": ["9746770"]}, {"Citation": "Billstrom R, Johansson B, Fioretos T, et al. Poor survival in t(8;21) (q22;q22)-associated acute myeloid leukaemia with leukocytosis. Eur J Haematol. 1997;59:47\u201352.", "ArticleIdList": ["9260580"]}, {"Citation": "Leblanc T, Berger R. Molecular cytogenetics of childhood acute myelogenous leukaemias. Eur J Haematol. 1997;59:1\u201313.", "ArticleIdList": ["9260575"]}, {"Citation": "Lee KW, Choi IS, Roh EY, et al. Adult patients with t(8;21) acute myeloid leukemia had no superior treatment outcome to those without t(8;21): a single institution's experience. Ann Hematol. 2004;83:218\u2013224.", "ArticleIdList": ["14628154"]}, {"Citation": "Matsumoto Y, Mori M, Ohtsuki T, et al. [Outcome of acute myelogenous leukemia in 41 patients treated with idarubicin: the prognosis of t(8;21) cases]. Rinsho Ketsueki. 2001;42:15\u201322.", "ArticleIdList": ["11235129"]}, {"Citation": "Cho EK, Bang SM, Ahn JY, et al. Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia. Korean J Intern Med. 2003;18:13\u201320.", "ArticleIdList": ["PMC4531607", "12760263"]}, {"Citation": "Zhu XH, Shen YL, Jing YK, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst. 1999;91:772\u2013778.", "ArticleIdList": ["10328107"]}, {"Citation": "Brown D, Kogan S, Lagasse E, et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 1997;94:2551\u20132556.", "ArticleIdList": ["PMC20126", "9122233"]}, {"Citation": "LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002;62:4996\u20135000.", "ArticleIdList": ["12208752"]}, {"Citation": "Nicholson DW. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 1999;6:1028\u20131042.", "ArticleIdList": ["10578171"]}, {"Citation": "Cohen GM. Caspases: the executioners of apoptosis. Biochem J. 1997;326(pt 1):1\u201316.", "ArticleIdList": ["PMC1218630", "9337844"]}, {"Citation": "Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002;108:153\u2013164.", "ArticleIdList": ["11832206"]}, {"Citation": "Nuchprayoon I, Meyers S, Scott LM, et al. PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2 beta/CBF beta proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells. Mol Cell Biol. 1994;14:5558\u20135568.", "ArticleIdList": ["PMC359075", "8035830"]}, {"Citation": "Britos-Bray M, Friedman AD. Core binding factor cannot synergistically activate the myeloperoxidase proximal enhancer in immature myeloid cells without c-Myb. Mol Cell Biol. 1997;17:5127\u20135135.", "ArticleIdList": ["PMC232363", "9271390"]}, {"Citation": "Austin GE, Zhao WG, Regmi A, Lu JP, Braun J. Identification of an upstream enhancer containing an AML1 site in the human myeloperoxidase (MPO) gene. Leuk Res. 1998;22:1037\u20131048.", "ArticleIdList": ["9783807"]}, {"Citation": "Nervi C, Ferrara FF, Fanelli M, et al. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood. 1998;92:2244\u20132251.", "ArticleIdList": ["9746761"]}, {"Citation": "Zhu J, Gianni M, Kopf E, et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci U S A. 1999;96:14807\u201314812.", "ArticleIdList": ["PMC24729", "10611294"]}, {"Citation": "Huang G, Shigesada K, Ito K, et al. Dimerization with PEBP2{beta} protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation. EMBO J. 2001;20:723\u2013733.", "ArticleIdList": ["PMC145428", "11179217"]}]}], "History": [{"Year": "2007", "Month": "1", "Day": "2", "Hour": "9", "Minute": "0"}, {"Year": "2007", "Month": "5", "Day": "24", "Hour": "9", "Minute": "0"}, {"Year": "2007", "Month": "1", "Day": "2", "Hour": "9", "Minute": "0"}, {"Year": "2008", "Month": "4", "Day": "15"}], "PublicationStatus": "ppublish", "ArticleIdList": ["17197433", "PMC1852250", "10.1182/blood-2006-06-032250", "S0006-4971(20)41721-5"]}}], "PubmedBookArticle": []}